Swedish Orphan Biovitrum
CompanySwedenFounded 2010
Swedish Orphan Biovitrum develops one asset, approved (anakinra in arthritis). Mostly protein or enzyme acting on inflammation and IL1R1; based in Sweden, founded in 2010.
- 1
- Asset
- Furthest
- Approved
- 11
- Trials
- 1
- Signal
Pipeline
1Recombinant interleukin-1 receptor antagonist blocking the biological activity of IL-1alpha and IL-1beta
Approved, Protein or enzyme, Inflammation, IL1R1, arthritis, Arthritis, Rheumatoid
Full company profiles: pipeline, trials, funding and people.
See ProIn the full profile
- Evidence behind the mechanisms3
- Trials20
- Signals1
- Similar companies6
Updated 10 Oct 2026 · 32 sources